Hamid Rezaee1,2, Shadi Abbasnia3,2, Anita Alenabi4, Rosita Vakili3, Nasrin Moheghi5, Jalil Tavakol Afshari6, Seyed Abdolrahim Rezaee3. 1. Neurosurgery Department, Mashhad University of Medical Sciences, Mashhad, Iran. 2. The first and the second authors contributed equally to this work. 3. Immunology Research Centre, Inflammation and inflammatory Diseases division, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Shariati Hospital, Department of Pathology, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Genetic Laboratory, Qaem Hosp. Mashhad University of Medical Sciences, Mashhad, Iran. 6. Immunology Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
BACKGROUND: Vascular endothelial growth factor (VEGF) is one of the primary angiogenesis regulators in solid cancers. Brain solid tumors are life-threatening diseases in which angiogenesis is an important phase of tumor development and progression. In the present study, VEGF-A and VEGF receptor (VEGF-R1) gene expression was evaluated in CNS brain tumors. METHODS: VEGF-A and VEGF-R1 expression was quantified using real-time PCR on fresh biopsies of 38 supratentorial brain tumors compared to 30 non-tumoral tissues. Then, the correlations were investigated with clinic-pathological and demographic factors of the patients. RESULTS: PCR product sequencing confirmed the validity of qRT-PCR. Although VEGF-A and VEGF-R1 expression showed increasing trends with the progression of cell proliferation in different stages of astrocytoma, VEGF-R1 did not meet the 95% confidence interval in other brain tumors. An increasing trend in VEGF-A expression and a declining trend in VEGF-R1 expression from Stage I to II were observed in meningioma. VEGF-A and VEGF-R1 expression had no significant correlation with age and gender. Although peritumoral brain edema (PTBE) in astrocytoma was significantly associated with tumor stages, VEGF-A and VEGF-R1 were not correlated with PTBE in meningioma and metastasis. CONCLUSION: VEGF-A is a valuable factor for the prognosis of PTBE and malignancy in astrocytoma and is helpful in monitoring treatment approaches.
BACKGROUND: Vascular endothelial growth factor (VEGF) is one of the primary angiogenesis regulators in solid cancers. Brain solid tumors are life-threatening diseases in which angiogenesis is an important phase of tumor development and progression. In the present study, VEGF-A and VEGF receptor (VEGF-R1) gene expression was evaluated in CNS brain tumors. METHODS: VEGF-A and VEGF-R1 expression was quantified using real-time PCR on fresh biopsies of 38 supratentorial brain tumors compared to 30 non-tumoral tissues. Then, the correlations were investigated with clinic-pathological and demographic factors of the patients. RESULTS: PCR product sequencing confirmed the validity of qRT-PCR. Although VEGF-A and VEGF-R1 expression showed increasing trends with the progression of cell proliferation in different stages of astrocytoma, VEGF-R1 did not meet the 95% confidence interval in other brain tumors. An increasing trend in VEGF-A expression and a declining trend in VEGF-R1 expression from Stage I to II were observed in meningioma. VEGF-A and VEGF-R1 expression had no significant correlation with age and gender. Although peritumoral brain edema (PTBE) in astrocytoma was significantly associated with tumor stages, VEGF-A and VEGF-R1 were not correlated with PTBE in meningioma and metastasis. CONCLUSION: VEGF-A is a valuable factor for the prognosis of PTBE and malignancy in astrocytoma and is helpful in monitoring treatment approaches.
Authors: G Stockhammer; A Obwegeser; H Kostron; P Schumacher; A Muigg; S Felber; H Maier; I Slavc; E Gunsilius; G Gastl Journal: Acta Neuropathol Date: 2000-07 Impact factor: 17.088
Authors: R A Berkman; M J Merrill; W C Reinhold; W T Monacci; A Saxena; W C Clark; J T Robertson; I U Ali; E H Oldfield Journal: J Clin Invest Date: 1993-01 Impact factor: 14.808
Authors: S Pistolesi; G Fontanini; T Camacci; K De Ieso; L Boldrini; G Lupi; R Padolecchia; R Pingitore; G Parenti Journal: J Neurooncol Date: 2002-11 Impact factor: 4.130
Authors: Joanna Reszec; Adam Hermanowicz; Robert Rutkowski; Grzegorz Turek; Zenon Mariak; Lech Chyczewski Journal: Biomed Res Int Date: 2015-03-03 Impact factor: 3.411